<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989091</url>
  </required_header>
  <id_info>
    <org_study_id>GL-CL-0001</org_study_id>
    <nct_id>NCT01989091</nct_id>
  </id_info>
  <brief_title>Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC</brief_title>
  <official_title>Multi-Center, Prospective, Randomized, Open-Label, Sponsor-Blinded, Active-Control (Heparin) Clinical Investigation to Evaluate the Safety and Effectiveness of B-Lock™ as an Antimicrobial Catheter Lock Solution in Dialysis Patients With a Central Venous Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Lakes Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Great Lakes Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: B-Lock is a safe and effective catheter lock solution that will maintain
      catheter patency and reduce Central Line Associated Blood Stream Infections (CLABSI) in
      dialysis patients using a central venous catheter (CVC) for vascular access.

      The study is a prospective, randomized, site unblinded/sponsor blinded, clinical study of a
      minimum of 300 dialysis patients using a central venous catheter (CVC) for vascular access.
      Patients will be randomized 1:1 to receive either the investigational medical device (B-Lock
      or IMD) or active control heparin (5000 U/mL) (ACH) and observed for a minimum of 45 days or
      a maximum of 273 (expected average 160 days).  IMD or ACH will be instilled into the
      catheter lumens (dual lumen catheters) at the end of each dialysis session and removed prior
      to the initiation of the next dialysis session.

      The primary objectives of this study are:

        -  To demonstrate the safety of B-Lock in dialysis patients

        -  To demonstrate the non-inferiority or, if proven to be non-inferior, superiority of
           B-Lock relative to ACH with respect to maintaining catheter patency as defined by the
           use of recombinant tissue plasminogen activator for maintaining adequate blood flow
           through the dialysis catheter

        -  To demonstrate the superiority of B-Lock relative to ACH with respect to the incidence
           of CLABSI
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The number of adverse events (AEs), serious adverse events (SAEs) and device deficiencies (DDs) in the experimental and control populations</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of thrombolytic treatment events in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Thrombolytic treatments may be required to maintain catheter blood flow rates when blood flow is measured under standardized conditions and compared to blood flow at study entry.  The number of treatment events in the experimental and control populations is inversely related to the ability of the lock solution to maintain catheter patency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of Central Line Associated Blood Stream Infections (CLABSI events) in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>CLABSI is defined by the CDC as a documented blood stream infection (bacterial or fungal) in a patient with a CVC with no other source of infection identified by a qualified physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of Lock Solution Failures in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>&quot;Lock Solution Failure&quot; is defined as the sum of CLABSI events plus Occlusive Malfunction events.  Occlusive malfunction is defined as the inability to return catheter blood flow rates to greater than 80% of baseline blood flow measrued at study entry under standardized conditions after treatment with tissue plasminogen activator (thrombolytic treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of Occlusive Malfunction events in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lock solution aspirate cultures that are positive for bacterial or fungal growth in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of catheters removed from the experimental and control patients that are found to have bacterial or fungal biofilm present inside the catheter lumen(s).</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter blood flow rates measured under standardized conditions over the duration of the study in the experimental and control populations.</measure>
    <time_frame>39 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Dialysis Catheter Infections</condition>
  <arm_group>
    <arm_group_label>B-Lock (IMD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Medical Device (IMD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin 5,000 U/mL (ACH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator Heparin (ACH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B-Lock</intervention_name>
    <description>Antimicrobial Catheter Lock Solution</description>
    <arm_group_label>B-Lock (IMD)</arm_group_label>
    <other_name>IMD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin 5,000 U/mL</intervention_name>
    <description>Standard of Care Catheter Lock Solution</description>
    <arm_group_label>Heparin 5,000 U/mL (ACH)</arm_group_label>
    <other_name>ACH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients age 18 to 80 years, inclusive. Patients, age 81 to 85 years,
             inclusive, may be included on a case-by-case basis if their health status is
             determined to be stable after consultation with the Medical Monitor.

          -  Patients with end-stage renal disease receiving hemodialysis via CVC.

          -  Patients must be expected to receive hemodialysis through a direct or cuffed,
             tunneled dual lumen catheter or 2 cuffed, tunneled single lumen catheters for a
             minimum of 45 catheter-days after Day 1.

          -  Patients must have been receiving dialysis for a minimum of 6 dialysis sessions at
             the study center dialysis clinic prior to the signing of the Informed Consent Form
             (ICF).

          -  Patients must have received dialysis at their prescribed blood flow rate (+/- 10%)
             for at least 2 consecutive dialysis sessions prior to signing the ICF.

          -  Patients must have 2 screening pre-pump arterial pressure measurements (collected
             during the first 20 minutes of dialysis) that differ by less than or equal to (≤) 20
             mmHg at 2 consecutive dialysis sessions when receiving dialysis at their prescribed
             blood flow rate (+/- 10%) prior to randomization.

        Exclusion Criteria:

          -  Clinical signs and/or symptoms of a local or systemic infection within 14 days prior
             to Day 1.

          -  Evidence of infection of the catheter exit site/tunnel within 14 days prior to Day 1.

          -  Patients who have received systemic antibiotics within 14 days prior to Day 1.

          -  History of fever (T &gt; 37.5°C) or chills within 14 days prior to Day 1.

          -  An occluded catheter (blood flow inadequate for dialysis) or a catheter that required
             thrombolytic treatment within 14 days prior to Day 1.

          -  A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic
             agent, including heparin.

          -  A catheter coated or impregnated with an antithrombotic, antimicrobial or antiseptic
             agent, including heparin.

          -  Catheters that are deemed by their manufacturers to be incompatible with
             alcohol-containing solutions. These include, but are not limited to:

               1. Angiodynamics - LifeJet® VP VascPak Catheter.

               2. Angiodynamics - Schon™ Chronic Hemodialysis Catheter.

               3. Angiotech - Hemostream™ Chronic Dialysis Catheter.

               4. Bard - all Bard Catheters.

          -  The use of TEGO® or TEGO-like catheter caps. Patients may be switched to standard
             catheter caps in order to participate in this study.

          -  Patients with a known or documented allergy to TMP or TMP-containing drugs, ethanol,
             ethylene diamine tetraacetic acid (EDTA), propylene glycol and/or glycerin.

          -  Patients with a history of heparin-induced thrombocytopenia or in whom the use of
             heparin is contraindicated. (Note: If the use of heparin is restricted for only a
             specified period of time, the patient may be enrolled at a later date when the use of
             heparin is no longer contraindicated.)

          -  Evidence of acute/ongoing hepatic injury (alanine aminotransferase [ALT] &gt; 300 IU/L)
             or chronic hepatic insufficiency (Total bilirubin &gt; 2.0 mg/dL and/or albumin &lt; 3.0
             g/dL during Screening or within 30 days prior to Screening). Note: A patient whose
             albumin level is low solely due to nephrotic syndrome may be enrolled (with Medical
             Monitor approval) if the albumin level has been stable for at least 3 months prior to
             ICF signature.

          -  Patients who the Investigator believes have a prognosis for survival of less than 3
             months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Cheronis, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Great Lakes Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John C Cheronis, MD PhD</last_name>
    <phone>303-435-4074</phone>
    <email>jcheronis@glpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Johnson, RPh</last_name>
    <phone>303-257-9542</phone>
    <email>sjohnson@glpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FMC Szépvölgyi Dialízis Központ</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ottó Árkossy, MD</last_name>
      <phone>36 20 9676226</phone>
      <email>otto.arkossy@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Ottó Árkossy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Dialízis Központ Péterfy S. Kórház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Csaba Rikker, MD</last_name>
      <phone>36 20 8047801</phone>
      <email>csaba.rikker@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Csaba Rikker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Dialízis Központ Szent István Kórház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Harsányi, MD</last_name>
      <phone>36 70 8667990</phone>
      <email>judit.harsanyi@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Judit Harsányi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DE OEC Nephrologiai Tanszék</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>József Balla, MD</last_name>
      <phone>36 52 413 653</phone>
      <email>balla@internal.med.unideb.hu</email>
    </contact>
    <investigator>
      <last_name>József Balla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Dialízis Központ Eger</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Péter Nagy, MD</last_name>
      <phone>36 70 376 8923</phone>
      <email>peter.nagy@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Péter Nagy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Dialízis Központ Kecskemét</name>
      <address>
        <city>Kecskémet</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sándor Keresztesi, MD</last_name>
      <phone>36 20 439 6543</phone>
      <email>sandor.keresztesi@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Sandor Keresztesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Nefrológiai Központ Miskolc</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erzsébet Ladányi, MD</last_name>
      <phone>36 20 954 1177</phone>
      <email>erzsebet.ladanyi@fmc-ag.com</email>
    </contact>
    <investigator>
      <last_name>Erzsébet Ladányi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FMC Dialízis Központ Pécs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>FMC Szatellita Dialízis Központ Pécs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán Ondrik, MD</last_name>
      <phone>36 202 533 732</phone>
      <email>zoltan.ondrik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zoltan Ondrik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ w NZOZ Centrum Chorób Wewnętrzynych &quot;EL-VITA&quot; w Elblągu</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Majewski, MD</last_name>
      <phone>48 698417793</phone>
      <email>adam.majewski@avitum.com.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Majewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Nefrologii, Transplantologii i Chorób Wewn</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bolesław Rutkowski, MD</last_name>
      <phone>48 58 349 2505</phone>
      <email>bolo@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Bolesław Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ NZOZ Diaverum</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <phone>48 664479338</phone>
      <email>przemyslaw.rutkowski@diaverum.com</email>
    </contact>
    <investigator>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Diaverum Gdańsk Kartuska, Stacja Dializ</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <phone>48 664479338</phone>
      <email>przemyslaw.rutkowski@diaverum.com</email>
    </contact>
    <investigator>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ NZOZ Avitum w Legnicy</name>
      <address>
        <city>Legnica</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Drozd, MD</last_name>
      <phone>48 509013512</phone>
      <email>adam.drozd@avitum.com.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Drozd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ NZOZ Avitum w Miechowie</name>
      <address>
        <city>Miechów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Kolarz, MD</last_name>
      <phone>48 602759895</phone>
      <email>marek.kolarz@avitum.com.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Kolarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H. Święcickiego, Oddział Nefrologii, Pododdział Dializ</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Oko, MD</last_name>
      <phone>48 61 8691605</phone>
      <email>aoko@ump.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Andrzej Oko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radomski Szpital Specjalistyczny im. T. Chałubińskiego, Oddział Dializ</name>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ NZOZ Diaverum w Tczewie</name>
      <address>
        <city>Tczew</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <phone>48 662245690</phone>
      <email>przemyslaw.rutkowski@diaverum.com</email>
    </contact>
    <investigator>
      <last_name>Przemysław Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stacja Dializ NZOZ Avitum w Zgierzu</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Wyroślak</last_name>
      <phone>48 604789624</phone>
      <email>janusz.wyroslak@avitum.com.pl</email>
    </contact>
    <investigator>
      <last_name>Janusz Wyroślak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniw. Szpital Kliniczny im. N.Barlickiego,Oddział Nefrologii, Pododdział Dializ</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michał Nowicki, MD</last_name>
      <phone>48 601561664</phone>
      <email>nefro@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Michał Nowicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.glpharma.com/</url>
    <description>Homepage</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney dialysis</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>locking solution</keyword>
  <keyword>antimicrobial</keyword>
  <keyword>thrombolytic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
